ArticleVirchows Archiv : an international journal of pathology2026
Comparison of immunohistochemical HER2 low detection in breast cancer using two antibodies assays in an interlaboratory study.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The identification of HER2-low expression has become critical for breast cancer treatment decisions in recent years. We retrospectively assessed the prevalence of HER2-low in 2270 samples using different immunohistochemistry (IHC) assays in three reference laboratories (LAB) of the same pathology network in Brazil. From 2021 to 2023, LAB A and LAB B routinely used Dako anti-c-erbB-2 polyclonal antibody (A0485) on Autostainer Link 48 Agilent/Dako and had HER2-low prevalence of 16 to 19%. In contrast, Lab C was using PATHWAY® anti-HER-2/neu (4B5) antibody on Benchmark Ultra instrument and found that 44% of the samples had HER2-low expression. We then prospectively analyzed 103 HER2-negative samples from LAB A (as per Dako A0845) and detected a switch from HER2-zero to HER2-low in 48% and to HER2-ultralow in 12%. Finally, 87 HER2-negative samples from LAB B (as per Dako A0485) were sent to LAB A for re-scoring by another pathologist, with no discordances in HER2-low status. Our data show that HER2 expression can be strongly influenced by the antibody assay used, with the highest HER2-low and HER2-ultralow detection with the Ventana 4B5 assay, as in pivotal clinical trials in these indications.
Indexed as
Identifiers
40715555What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.